search
Back to results

Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer

Primary Purpose

Early Gastric Cancer

Status
Not yet recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
endoscopic submucosal dissection
Surgery
Sponsored by
Peking University Third Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Early Gastric Cancer focused on measuring early gastric cancer, endoscopic submucosal dissection, surgery

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinically diagnosed as early gastric cancer
  • Willing to undergo endoscopic submucosal dissection or surgery for the treatment of early gastric cancer

Exclusion Criteria:

  • Advanced stage gastric cancer
  • Not willing to undergo endoscopic submucosal dissection or surgery for the treatment of early gastric cancer
  • Not willing to participate in this study

Sites / Locations

  • Peking University Third Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

ESD group

Surgery group

Arm Description

This group include patients who are going to undergo endoscopic submucosal dissection for early gastric cancer.

This group include patients who are going to undergo surgery for early gastric cancer.

Outcomes

Primary Outcome Measures

5-year OS
5-year OS is the five year overall survival of each individual group. It will be estimated by Kaplan-Meier method, and statistical significance of differences between the two groups will be assessed using the log-rank test.
5-year DSS
5-year DSS is the five year disease specific survival of each individual group. It will be estimated by Kaplan-Meier method, and statistical significance of differences between the two groups will be assessed using the log-rank test.

Secondary Outcome Measures

Complication
Complications were classified according to the Clavien-Dindo classification and the frequency of the complications will be compared between the two groups.

Full Information

First Posted
February 25, 2019
Last Updated
February 27, 2019
Sponsor
Peking University Third Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03857737
Brief Title
Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer
Official Title
A Study Which Compares the Long Term and Short Term Outcomes Between Endoscopic Submucosal Dissection and Surgery in the Treatment of Early Gastric Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Not yet recruiting
Study Start Date
March 1, 2019 (Anticipated)
Primary Completion Date
December 31, 2029 (Anticipated)
Study Completion Date
December 31, 2029 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Peking University Third Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
In this study, patients who are going to undergo endoscopic submucosal dissection (ESD) or surgery for early gastric cancer will be enrolled and divided into ESD group and Surgery group according to the procedure they go through. The patients will be followed up for at least 5 years after ESD or surgery. Esophagogastroduodenoscopy (EDG) and biopsy will be performed 3 months and then 6 months after ESD or surgery. Thereafter, EDG will be performed along with biopsy and abdominal computed tomography annually up to 5 years. Patients' data such as age, sex, clinical diagnosis, achievement of en-bloc resection, pathological outcomes, complications and survival condition will be prospectively collected. Statistical methods such as Student's t-test, the chi-square test, the Kaplan-Meier method and the log-rank test will be used to compare the short term and long term outcomes between the ESD group and the surgery group.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Early Gastric Cancer
Keywords
early gastric cancer, endoscopic submucosal dissection, surgery

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ESD group
Arm Type
Experimental
Arm Description
This group include patients who are going to undergo endoscopic submucosal dissection for early gastric cancer.
Arm Title
Surgery group
Arm Type
Active Comparator
Arm Description
This group include patients who are going to undergo surgery for early gastric cancer.
Intervention Type
Procedure
Intervention Name(s)
endoscopic submucosal dissection
Intervention Description
Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists.
Intervention Type
Procedure
Intervention Name(s)
Surgery
Intervention Description
Surgery for EGC include Distal, proximal, or total gastrectomy, which will be performed according to the location and macroscopic tumor type by experienced surgeons.
Primary Outcome Measure Information:
Title
5-year OS
Description
5-year OS is the five year overall survival of each individual group. It will be estimated by Kaplan-Meier method, and statistical significance of differences between the two groups will be assessed using the log-rank test.
Time Frame
From March 1 2019 to December 1 2024
Title
5-year DSS
Description
5-year DSS is the five year disease specific survival of each individual group. It will be estimated by Kaplan-Meier method, and statistical significance of differences between the two groups will be assessed using the log-rank test.
Time Frame
From March 1 2019 to December 1 2024
Secondary Outcome Measure Information:
Title
Complication
Description
Complications were classified according to the Clavien-Dindo classification and the frequency of the complications will be compared between the two groups.
Time Frame
From March 1 2019 to December 1 2024

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinically diagnosed as early gastric cancer Willing to undergo endoscopic submucosal dissection or surgery for the treatment of early gastric cancer Exclusion Criteria: Advanced stage gastric cancer Not willing to undergo endoscopic submucosal dissection or surgery for the treatment of early gastric cancer Not willing to participate in this study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shigang Ding, MD
Phone
+8618800105276
Email
18800105276@163.com
Facility Information:
Facility Name
Peking University Third Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100091
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shigang Ding, MD
First Name & Middle Initial & Last Name & Degree
Shigang Ding, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
27342689
Citation
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017 Jan;20(1):1-19. doi: 10.1007/s10120-016-0622-4. Epub 2016 Jun 24. No abstract available.
Results Reference
background
PubMed Identifier
27722825
Citation
Suzuki H, Oda I, Abe S, Sekiguchi M, Nonaka S, Yoshinaga S, Saito Y, Fukagawa T, Katai H. Clinical outcomes of early gastric cancer patients after noncurative endoscopic submucosal dissection in a large consecutive patient series. Gastric Cancer. 2017 Jul;20(4):679-689. doi: 10.1007/s10120-016-0651-z. Epub 2016 Oct 8.
Results Reference
background
PubMed Identifier
30207593
Citation
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum In: CA Cancer J Clin. 2020 Jul;70(4):313.
Results Reference
background
PubMed Identifier
26317585
Citation
Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, Repici A, Vieth M, De Ceglie A, Amato A, Berr F, Bhandari P, Bialek A, Conio M, Haringsma J, Langner C, Meisner S, Messmann H, Morino M, Neuhaus H, Piessevaux H, Rugge M, Saunders BP, Robaszkiewicz M, Seewald S, Kashin S, Dumonceau JM, Hassan C, Deprez PH. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015 Sep;47(9):829-54. doi: 10.1055/s-0034-1392882. Epub 2015 Aug 28.
Results Reference
background

Learn more about this trial

Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer

We'll reach out to this number within 24 hrs